This trade activity should not be overlooked: Harmony Biosciences Holdings Inc (HRMY)

With 1.17 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.74 million shares. The 52-week range on HRMY shows that it touched its highest point at $41.61 and its lowest point at $26.47 during that stretch. It currently has a 1-year price target of $51.00. Beta for the stock currently stands at 0.82.

Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of HRMY was up-trending over the past week, with a rise of 13.47%, but this was up by 17.75% over a month. Three-month performance dropped to -15.04% while six-month performance rose 1.09%. The stock gained 5.92% in the past year, while it has lost -2.82% so far this year. A look at the trailing 12-month EPS for HRMY yields 2.62 with Next year EPS estimates of 4.03. For the next quarter, that number is 0.75. This implies an EPS growth rate of 25.57% for this year and 27.93% for next year.

Float and Shares Shorts:

At present, 57.39 million HRMY shares are outstanding with a float of 43.54 million shares on hand for trading.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for HRMY since 6 analysts follow the stock currently. There are 5 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 1 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential.

EPS: Estimates vs Actual

It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of $2.54885 being high and $2.07397 being low. For HRMY, this leads to a yearly average estimate of $2.35502.